Skip to content
Research · Sep 26, 2026

Microsoft open-sources RetroChimera, a retrosynthesis model for small-molecule synthesis planning

The model combines two complementary sub-models and outperforms prior approaches in blind tests with PhD-level chemists, with code and weights released under an open-source license.

Trust79
HypeLow hype

1 source · cross-referenced

ShareXLinkedInEmail
TL;DR
  • Microsoft Research describes RetroChimera, a new retrosynthesis model published in Nature that accelerates planning for small-molecule synthesis.

Microsoft Research announced RetroChimera, a retrosynthesis model published in the journal Nature that proposes synthesis routes for small molecules by working backward from a target molecule to purchasable building blocks.

The model combines two sub-models with complementary strengths: R-SMILES 2, a Transformer-based de novo model that predicts precursors directly from the input molecule, and NeuralLoc, a graph neural network model that selects reaction templates and applies them to the target molecule.

RetroChimera uses a learned ensembling strategy to rank and combine predictions from both sub-models, leveraging their complementary strengths across reaction types, including rare reactions.

In blind tests, PhD-level chemists preferred RetroChimera’s individual reaction predictions over preceding models and recorded literature reactions, and the model succeeded on nine out of ten challenging targets in expert assessments of multistep synthesis routes.

The team reports successful zero-shot transfer and fine-tuning on proprietary datasets, and they open-sourced RetroChimera’s implementation and weights to enable researchers to accelerate development of medicinally relevant molecules and advanced materials.

Sources
  1. 01Microsoft Research — Improving synthesis prediction of small molecules at scale with RetroChimera
Also on Research

Stories may contain errors. Dispatch is assembled with AI assistance and curated by human editors; despite the trust-score filter, mistakes happen. We correct publicly — every article links to its revision history. Nothing here is financial, legal, or medical advice. Verify before relying on any claim.

© 2026 Dispatch. No ads. No sponsorships. No paid placement. Reader-supported via Ko-fi.

Built by a person who cares about honest AI news.